These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18284634)

  • 21. The RET functional variant c 587T>C is not associated with susceptibility to sporadic medullary thyroid cancer.
    Fernández RM; Sánchez-Mejías A; Navarro E; López-Alonso M; Antiñolo G; Borrego S
    Thyroid; 2009 Sep; 19(9):1017-8. PubMed ID: 19678735
    [No Abstract]   [Full Text] [Related]  

  • 22. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma.
    Wiench M; Włoch J; Wygoda Z; Gubała E; Oczko M; Pawlaczek A; Kula D; Lange D; Jarzab B
    Cancer Detect Prev; 2004; 28(4):231-6. PubMed ID: 15350625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer.
    Khan MS; Pandith AA; Iqbal M; Naykoo NA; Khan SH; Rather TA; Mudassar S
    J Cell Biochem; 2015 Aug; 116(8):1712-8. PubMed ID: 25736215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
    Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
    Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
    Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
    Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients].
    Wohllk G N; Soto C E; Bravo A M; Becker C P
    Rev Med Chil; 2005 Apr; 133(4):397-402. PubMed ID: 15953945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 "Janus" genetic variation.
    Moore SW; Zaahl M
    J Pediatr Surg; 2010 Feb; 45(2):393-6. PubMed ID: 20152359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Genetic polymorphisms: implications in the pathogenesis of medullary thyroid carcinoma].
    Rocha AP; Magalhães PK; Maia AL; Maciel LM
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):723-30. PubMed ID: 17891235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.
    Sromek M; Czetwertyńska M; Skasko E; Zielińska J; Czapczak D; Steffen J
    Endocr Pathol; 2010 Sep; 21(3):178-85. PubMed ID: 20521125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
    Sawai H; Okada Y; Kazanjian K; Kim J; Hasan S; Hines OJ; Reber HA; Hoon DS; Eibl G
    Cancer Res; 2005 Dec; 65(24):11536-44. PubMed ID: 16357163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RET 3'UTR polymorphisms and its protective role in Hirschsprung disease in southeastern Chinese.
    Pan ZW; Luo CF; Liu ZJ; Li JC
    J Pediatr Surg; 2012 Sep; 47(9):1699-705. PubMed ID: 22974609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
    Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
    J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study.
    Lantieri F; Caroli F; Ceccherini I; Griseri P
    Int J Cancer; 2013 Jun; 132(12):2808-19. PubMed ID: 23180660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease.
    Fitze G; Schierz M; Kuhlisch E; Schreiber M; Ziegler A; Roesner D; Schackert HK
    Hum Mutat; 2003 Aug; 22(2):177. PubMed ID: 12872262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A common haplotype at the 5' end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression.
    Griseri P; Bachetti T; Puppo F; Lantieri F; Ravazzolo R; Devoto M; Ceccherini I
    Hum Mutat; 2005 Feb; 25(2):189-95. PubMed ID: 15643606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.